Unicycive Therapeutics Stock Alpha and Beta Analysis
| UNCY Stock | USD 0.54 0.03 4.91% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Unicycive Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Unicycive Therapeutics over a specified time horizon. Remember, high Unicycive Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Unicycive Therapeutics' market risk premium analysis include:
Beta 1.26 | Alpha 0.46 | Risk 5.16 | Sharpe Ratio (0.04) | Expected Return (0.23) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Unicycive |
Unicycive Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Unicycive Therapeutics market risk premium is the additional return an investor will receive from holding Unicycive Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Unicycive Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Unicycive Therapeutics' performance over market.| α | 0.46 | β | 1.26 |
Unicycive Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Unicycive Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Unicycive Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Unicycive Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Unicycive Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Unicycive Therapeutics shares will generate the highest return on investment. By understating and applying Unicycive Therapeutics stock market price indicators, traders can identify Unicycive Therapeutics position entry and exit signals to maximize returns.
Unicycive Therapeutics Return and Market Media
The median price of Unicycive Therapeutics for the period between Wed, Nov 27, 2024 and Tue, Feb 25, 2025 is 0.65 with a coefficient of variation of 14.16. The daily time series for the period is distributed with a sample standard deviation of 0.09, arithmetic mean of 0.65, and mean deviation of 0.08. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Unicycive Therapeutics granted extension to meet Nasdaq compliance | 01/07/2025 |
2 | Unicycive Therapeutics, Inc. Short Interest Update - MarketBeat | 01/16/2025 |
3 | Unicycive Therapeutics Announces the Publication of Patient Perspectives on Phosphate Management in the Journal of Nephrological Science | 01/28/2025 |
4 | Comparing Unicycive Therapeutics and Imunon | 01/30/2025 |
5 | Disposition of 686 shares by Aggarwal Gaurav of Unicycive Therapeutics at 0.49 subject to Rule 16b-3 | 02/18/2025 |
6 | Unicycive Therapeutics Announces the Publication of Preclinical Data on Synergies Between Oxylanthanum Carbonate and Tenapanor in American Society of Nephrology... | 02/20/2025 |
About Unicycive Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Unicycive or other stocks. Alpha measures the amount that position in Unicycive Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2023 | 2024 | 2025 (projected) | Interest Debt Per Share | 0.0364 | 0.0418 | 0.0398 | Revenue Per Share | 0.0275 | 0.0316 | 0.0498 |
Unicycive Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Unicycive Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Unicycive Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Unicycive Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Unicycive Therapeutics. Please utilize our Beneish M Score to check the likelihood of Unicycive Therapeutics' management manipulating its earnings.
| 29th of March 2024 Upcoming Quarterly Report | View | |
| 21st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 29th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Unicycive Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Unicycive Stock Analysis
When running Unicycive Therapeutics' price analysis, check to measure Unicycive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Unicycive Therapeutics is operating at the current time. Most of Unicycive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Unicycive Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Unicycive Therapeutics' price. Additionally, you may evaluate how the addition of Unicycive Therapeutics to your portfolios can decrease your overall portfolio volatility.